Targeted radiation approach for prostate cancer without continuous castration

Who could benefit from this research

What this research studies

This project explores combining metastasis-directed SBRT with PSMA-targeted radiopharmaceuticals in men with mCRPC to see if we can reduce or avoid ongoing castration while maintaining cancer control. It emphasizes a patient-centered goal of better quality of life and hormonal function by potentially restoring physiologic testosterone during therapy. The approach uses precision radiation to treat metastatic lesions and integrates systemic targeted radiopharmaceuticals to enhance effectiveness. The study is grounded in real-world concerns about side effects from long-term castration and aims to identify a treatment window that supports vitality and daily living. Participation would involve coordinated imaging, radiation planning, and systemic therapy as part of a multi-modal treatment plan.

Why it matters

Where this research is happening

• VA Greater Los Angeles Healthcare System
  Los Angeles, United States Active

Researchers

• Principal investigator: Nickols, Nicholas George — VA Greater Los Angeles Healthcare System
• Study coordinator: Nickols, Nicholas George

Related research

Other NIH-funded projects on the same topics.

• Dual Targeting of B7-H3 in metastatic prostate cancer

  A Johns Hopkins team is testing two targeted therapies against B7-H3 to help people with metastatic castration-resistant prostate cancer feel better and show tumor responses.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11418390

• Hyperactive methylation in a hard-to-treat prostate cancer subtype

  Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11415138

• Extending Benefit by Targeting Resistant Lesions in mCRPC

  A cancer center plans to identify on-treatment resistant spots in men with metastatic castration-resistant prostate cancer and then use targeted local therapy to those spots while systemic treatment continues.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11398992

• CXCR1/2 inhibitor plus enzalutamide for abiraterone-resistant metastatic prostate cancer

  A phase 2 study tests whether adding SX-682 to enzalutamide helps men with advanced prostate cancer that no longer responds to abiraterone.

  NIH research Syntrix Biosystems, INC. · Auburn, United States · NIH-11370143

• Multidimensional approach to boost PSMA-RPT success in advanced prostate cancer

  A cancer research grant aims to better understand why PSMA-targeted radiopharmaceutical therapy works sometimes but not always for advanced prostate cancer, with the goal of making treatments more effective for patients who need them.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11360691

• Liquid biopsy test to guide HER2-targeted therapy for advanced prostate cancer

  A new liquid biopsy test using blood markers to pick and guide HER2-directed therapy for men with advanced, treatment-resistant prostate cancer.

  NIH research U.s. Dept/vets Affairs Medical Center · Washington, United States · NIH-11300143

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.